Last quarter (Q4 2023), CymaBay Therapeutics's total revenue was $57.00K, an increase of Infinity% from the same quarter last year. In Q4, CymaBay Therapeutics's net income was $-41.90M. See CymaBay Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 31.07M	$ 31.07M	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 31.07M	$ 31.07M	-	-	-	-
Operating Expense	$ 132.75M	$ 132.75M	$ 93.11M	$ -87.58M	$ 52.60M	$ 103.08M
Operating Income	$ -101.68M	$ -101.68M	$ -93.11M	$ -87.58M	$ -52.60M	$ -103.08M
Net Non Operating Interest Income Expense	$ -5.46M	$ -5.46M	$ -12.89M	$ -2.42M	$ 1.62M	$ 5.34M
Other Income Expense	$ -1.76M	$ -1.76M	-	-	$ 705.00K	$ -5.08M
Pretax Income	$ -105.37M	$ -105.37M	$ -106.00M	$ -90.00M	$ -50.99M	$ -102.81M
Tax Provision	$ -1.13M	$ -1.13M	-	$ -6.00K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -105.37M	$ -105.37M	$ -106.00M	$ -90.00M	$ -50.99M	$ -102.81M
Basic EPS	$ -0.97	$ -0.99	$ -1.21	$ -1.27	$ -0.74	$ -1.53
Diluted EPS	$ -0.97	$ -0.99	$ -1.21	$ -1.27	$ -0.74	$ -1.53
Basic Average Shares	$ 424.82M	$ 106.20M	$ 87.80M	$ 71.06B	$ 68.89M	$ 67.03M
Diluted Average Shares	$ 424.82M	$ 106.20M	$ 87.80M	$ 71.06M	$ 68.89M	$ 67.03M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 132.75M	$ 132.75M	$ 93.11M	$ -87.58M	$ 52.60M	$ 103.08M
Net Income From Continuing And Discontinued Operation	$ -105.37M	$ -105.37M	$ -106.00M	$ -90.00M	$ -50.99M	$ -102.81M
Normalized Income	$ -70.44M	$ -106.50M	$ -83.74M	-	$ -50.99M	$ -97.73M
Interest Expense	-	-	-	-	$ 0.00	$ 0.00
EBIT	$ -86.42M	$ -86.42M	$ -91.09M	$ -87.42M	$ -50.99M	$ -103.08M
EBITDA	$ -93.61M	$ -93.61M	$ -91.26M	$ -86.09M	$ -50.35M	$ -102.50M

Currency in USD

CymaBay Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing